Abbott Laboratories
NYSE:ABT
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
100.07
120.96
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Abbott Laboratories
Abbott Laboratories
Interest Income Expense
Abbott Laboratories
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abbott Laboratories
NYSE:ABT
|
Interest Income Expense
-$247m
|
CAGR 3-Years
21%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-12%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Interest Income Expense
-$364m
|
CAGR 3-Years
1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-15%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Interest Income Expense
-$564m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
2%
|
CAGR 10-Years
-11%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Interest Income Expense
$82.9m
|
CAGR 3-Years
84%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
Interest Income Expense
$127m
|
CAGR 3-Years
23%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Interest Income Expense
$315.7m
|
CAGR 3-Years
54%
|
CAGR 5-Years
21%
|
CAGR 10-Years
39%
|
|
Abbott Laboratories
Glance View
Abbott Laboratories, a global leader in the healthcare industry, has a storied history dating back to its founding in 1888 by Dr. Wallace Abbott. The company is renowned for its dedication to improving health through innovative products that span several key segments: diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. With a robust portfolio that includes cutting-edge technologies such as continuous glucose monitoring systems and rapid COVID-19 tests, Abbott has positioned itself as a vital player in both consumer and professional healthcare arenas. Its commitment to research and development, capturing nearly $2 billion in annual investment, underscores the company's strategic focus on innovation and long-term growth, making it an attractive option for investors seeking stability and upward trajectory in the healthcare sector. Abbott's diverse product offerings and strong market presence provide a solid foundation for its financial performance, which has consistently demonstrated resilience and growth across economic cycles. The company's ability to adapt to changing healthcare needs—exemplified by its rapid response to the COVID-19 pandemic with the development of at-home testing solutions—highlights its proactive approach and operational agility. In addition to its impressive revenue streams, Abbott pays a growing dividend, appealing to income-focused investors. With a clear vision for the future, bolstered by global expansion and strategic acquisitions, Abbott Laboratories is not just a company that manufactures healthcare products; it is a catalyst for positive change in health and well-being, making it a compelling investment opportunity for those looking to capitalize on the ever-evolving healthcare landscape.
See Also
What is Abbott Laboratories's Interest Income Expense?
Interest Income Expense
-247m
USD
Based on the financial report for Sep 30, 2024, Abbott Laboratories's Interest Income Expense amounts to -247m USD.
What is Abbott Laboratories's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
-12%
Over the last year, the Interest Income Expense growth was 2%. The average annual Interest Income Expense growth rates for Abbott Laboratories have been 21% over the past three years , 17% over the past five years , and -12% over the past ten years .
You don't have any saved screeners yet
